Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 31Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Biphenotypic, Acute 5Leukemia 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Sarcoma, Myeloid 2Myelodysplastic Syndromes 2Leukemia, Monocytic, Acute 2Hematologic Neoplasms 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasms 1Lymphoma, T-Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Basophilic, Acute 1Down Syndrome 1Acute Myeloid Leukemia With KMT2A Rearrangement 1

Interventions

Injections 2Gemtuzumab 2Decitabine 2Cytarabine 2fludarabine phosphate 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Daunorubicin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Acute × Daunorubicin × 90 days × Clear all
NCT01627041 2026-04-27

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
178 enrolled
Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡